What are Inovium-affiliated treatments?

Science once believed that women have a limited number of eggs which emerge from a finite number of primordial follicles produced during fetal development. Only these follicles were thought to develop to the grafian stage, in which the eggs ovulate. However, the revolutionary work of Dr. Tilly and his colleagues proved the contrary by the landmark discovery of Female Germline Stem Cells (FGSCs) in postnatal mammalian ovaries.[1]. Notably, these undifferentiated FGSCs were shown to differentiate and form oocytes or egg cells which challenged the belief of limited Ovarian Reserve. [2]. Secondly, ovarian aging causes disruption of ovulation cycle that leads to hormonal disparity and establishes the basis of female infertility. Consequently, the Premature Ovarian Failure and Menopause cause a decline in the overall wellbeing of women aged 35 and above 40 years respectively. Ovarian Rejuvenation may be the answer.

Inovium makes accessible a modern, highly effective fertility treatment which exploits the potential of Mesenchymal Stem Cells and Platelet Rich Plasma to restore youthful hormone levels, reverse menopause and address infertility by rejuvenating the ovaries. Ovarian rejuvenation is a relatively new concept, but the results so far offer the extraordinary promise that a woman in ovarian failure may give birth to offspring using her own eggs.

Take action

Start your treatment today!

How does Inovium provide access to the best treatments in on the market?

Inovium provides access to treatments which can be administered in the combination of IVF as it involves the injection of PRP and MSCs directly into the ovaries using ultrasound assisted needle. It provides a safe and remarkably efficacious alternative to Hormonal Replacement Therapy which has been shown to cause cancer and poor fertility outcome. [4].

“Recently, Platelet Rich Plasma (PRP) treatment emerged as a groundbreaking solution to reverse menopause and helped postmenopausal women achieve restored FSH and LH levels along with successful conceptions. Inovium was one of the leaders in bringing PRP to clinical trials in the US.

Inovium can provide you with access to treatments that are far more efficacious than the regular PRP treatment because it is the combination of PRP and MSCs. It has shown remarkable results in restoring hormone levels beyond that of PRP and has comparatively uniform fertility outcome due to strong rejuvenation impact.”

Have questions?

Write to us for answers!

Are the treatments safe?

Autologous cells are cells drawn from the patient herself. Inovium utilizes autologous PRP and Mesenchymal Stem Cells for transplantation. The stem cells lose their function, undergo DNA damage and suffer from low survival rate in vivo which may cause cancer or other serious infections. Inovium-affiliated treatments seek to overcome this challenge by using MSCs without prolonged incubation.

The use of the patient’s own blood plasma and bone marrow cells makes Inovium safest infertility and ovarian rejuvenation treatment which has a strong rejuvenation impact. Always consult your physician to determine if stem cell therapies are right for you. Inovium labs, LLC is not a clinic and does not provide the treatment. Our affiliate physicians are responsible for your treatment outcomes.

References

1. Johnson, Joshua, Jacqueline Canning, Tomoko Kaneko, James K. Pru, and Jonathan L. Tilly. “Germline stem cells and follicular renewal in the postnatal mammalian ovary.” Nature428, no. 6979 (2004): 145.
2. White, Yvonne AR, Dori C. Woods, Yasushi Takai, Osamu Ishihara, Hiroyuki Seki, and Jonathan L. Tilly. “Oocyte formation by mitotically active germ cells purified from ovaries of reproductive-age women.” Nature medicine 18, no. 3 (2012): 413.

3.Johnson, Joshua, Jessamyn Bagley, Malgorzata Skaznik-Wikiel, Ho-Joon Lee, Gregor B. Adams, Yuichi Niikura, Katherine S. Tschudy et al. “Oocyte generation in adult mammalian ovaries by putative germ cells in bone marrow and peripheral blood.” Cell 122, no. 2 (2005): 303-315.

4. Krieger, Nancy, Ilana Löwy, Robert Aronowitz, Judyann Bigby, Kay Dickersin, Elizabeth Garner, Jean-Paul Gaudilliere et al. “Hormone replacement therapy, cancer, controversies, and women’s health: historical, epidemiological, biological, clinical, and advocacy perspectives.” Journal of Epidemiology & Community Health 59, no. 9 (2005): 740-748.

5. Pantos, K., N. Nitsos, G. Kokkali, T. Vaxevanoglou, C. Markomichali, A. Pantou, M. Grammatis, L. Lazaros, and K. Sfakianoudis. “Ovarian rejuvenation and folliculogenesis reactivation in peri-menopausal women after autologous platelet-rich plasma treatment.” In Abstracts, ESHRE 32nd Annual Meeting, pp. 3-6. 2016.

6. Sills, E. Scott, Natalie S. Rickers, Xiang Li, and Gianpiero D. Palermo. “First data on in vitro fertilization and blastocyst formation after intraovarian injection of calcium gluconate-activated autologous platelet rich plasma.” Gynecological Endocrinology (2018): 1-5.

This section is in the process of being updated.

Check back later to see the up to date information